Innoxel Lifesciences Commences U.S. Commercial Supply

Innoxel Lifesciences Private Limited, a material subsidiary of Bharat Parenterals Limited, has commenced commercial supply to the United States market. The first product, manufactured under a contract manufacturing (CMO) arrangement at Innoxel's Vadodara facility, was launched in the U.S. on October 20, 2026. This marks a shift for Innoxel from licensing income to recurring commercial supply revenue. The facility has previously received an Establishment Inspection Report (EIR) from the U.S. FDA in July 2025 and an EU-GMP certificate in March 2026. Bharat Parenterals expects more CMO launches in the upcoming quarters.